1. Kyoto University Research Information Repository
  2. 060　医学研究科・医学部・医学部附属病院
  3. 学術雑誌掲載論文等
このアイテムのアクセス数: 454

    このアイテムの引用には次の識別子を使用してください: http://hdl.handle.net/2433/199863
このアイテムのファイル:
ファイル 記述 サイズフォーマット 
tid.12187.pdf162.98 kBAdobe PDF見る/開く
完全メタデータレコード
DCフィールド値言語
dc.contributor.authorKato, Ken
dc.contributor.authorNagao, Men
dc.contributor.authorNakano, Sen
dc.contributor.authorYunoki, Ten
dc.contributor.authorHotta, Gen
dc.contributor.authorYamamoto, Men
dc.contributor.authorMatsumura, Yen
dc.contributor.authorIto, Yen
dc.contributor.authorTakakura, Sen
dc.contributor.authorChen, Fen
dc.contributor.authorBando, Ten
dc.contributor.authorMatsuda, Yen
dc.contributor.authorMatsubara, Ken
dc.contributor.authorDate, Hen
dc.contributor.authorIchiyama, Sen
dc.contributor.alternative長尾, 美紀ja
dc.date.accessioned2015-09-14T01:42:01Z-
dc.date.available2015-09-14T01:42:01Z-
dc.date.issued2014-04-
dc.identifier.issn1399-3062-
dc.identifier.urihttp://hdl.handle.net/2433/199863-
dc.description.abstractInvasive Aspergillus infection (IA) is a significant cause of morbidity in lung transplantation (LT). However, its optimal prophylaxis is unclear. We routinely administer itraconazole (ITCZ) prophylaxis to all patients undergoing LT. In this study, we retrospectively evaluated the duration of prophylaxis and risk factors of IA. Among 30 adult patients who underwent LT, 5 patients developed IA. All patients with IA stopped ITCZ treatment within 1 year. At least 1 year of ITCZ prophylaxis is essential for the prevention of IA. Cytomegalovirus infection, renal replacement therapy, and tracheotomy were risk factors for IA.en
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherwileyen
dc.rightsThis is the peer reviewed version of the following article: K. Kato, M. Nagao, S. Nakano, T. Yunoki, G. Hotta, M. Yamamoto, Y. Matsumura, Y. Ito, S. Takakura, F. Chen, T. Bando, Y. Matsuda, K. Matsubara, H. Date, S. Ichiyama. Itraconazole prophylaxis for invasive Aspergillus infection in lung transplantation. Transpl Infect Dis 2014: 16: 340–343, which has been published in final form at http://dx.doi.org/10.1111/tid.12187. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.en
dc.rightsThis is not the published version. Please cite only the published version.en
dc.rightsこの論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。ja
dc.subjectlung transplantationen
dc.subjectitraconazoleen
dc.subjectinvasive Aspergillus infectionen
dc.subjecttherapeutic drug monitoringen
dc.subjectprophylaxis durationen
dc.subject.meshAdulten
dc.subject.meshAntibiotic Prophylaxisen
dc.subject.meshAntifungal Agents/therapeutic useen
dc.subject.meshCase-Control Studiesen
dc.subject.meshCytomegalovirus Infections/complicationsen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshItraconazole/therapeutic useen
dc.subject.meshLung Transplantationen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshPulmonary Aspergillosis/prevention & controlen
dc.subject.meshRenal Replacement Therapyen
dc.subject.meshRetrospective Studiesen
dc.subject.meshRisk Factorsen
dc.subject.meshTracheotomyen
dc.titleItraconazole prophylaxis for invasive Aspergillus infection in lung transplantation.en
dc.typejournal article-
dc.type.niitypeJournal Article-
dc.identifier.jtitleTransplant infectious diseaseen
dc.identifier.volume16-
dc.identifier.issue2-
dc.identifier.spage340-
dc.identifier.epage343-
dc.relation.doi10.1111/tid.12187-
dc.textversionauthor-
dc.startdate.bitstreamsavailable2015-05-01-
dc.identifier.pmid24593162-
dcterms.accessRightsopen access-
出現コレクション:学術雑誌掲載論文等

アイテムの簡略レコードを表示する

Export to RefWorks


出力フォーマット 


このリポジトリに保管されているアイテムはすべて著作権により保護されています。